Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

摘要: Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and panitumumab (P). We examined impact C P on progression-free survival (PFS), overall (OS) response rate (ORR) in advanced colorectal cancer (CRC) patients who have RAS-wt/BRAF-mutant (BRAF-mut) status. Methods Randomised trials that compared or plus chemotherapy (or monotherapy) with standard therapy best supportive care (BSC) were included. used published hazard ratios (HRs) if they available, we derived treatment estimates from other data. Pooled efficacy anti-EGFR-based for RAS-wt/BRAF-mut subgroup calculated random-effect inverse variance weighted method. All statistical tests two-sided. Results Nine phase III one II trial (six first-line two second-line trials, involving chemorefractory patients), included 463 CRC patients, analysed. Overall, addition BRAF-mut did not significantly improve PFS (HR, 0.88; 95% confidence interval (CI), 0.67–1.14; p = 0.33), OS 0.91; CI, 0.62–1.34; p = 0.63) ORR (relative risk, 1.31; CI 0.83–2.08, p = 0.25) control regimens. Conclusions C- P-based increase benefit BSC patients. These findings support BRAF mutation assessment before initiation anti-EGFR antibodies.